Company news

Bolt Metals Corp. (CSE:BOLT) news

Bolt Metals Corp. news releases on 6ix. Latest, Aug 11, 2026: Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Metals Corp. (CSE:BOLT) news

Press releases & updates

Bolt Biotherapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

Bolt Metals Announces Closing of Option to Acquire the High-Grade Floralia Iron Project

Bolt Metals Completes 402 line-km MobileMT Survey at Northwind Property, Quebec

Bolt Metals Executes Option to Acquire The High-Grade Floralia Iron Project, Prepares for Maiden Drill Program at Northwind

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

Bolt Metals Corp. Announces Appointment of Chief Financial Officer and Corporate Secretary

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

Bolt Metals Announces Upsize Non-Brokered Private Placement to $6,000,000

Bolt Metals Announces Private Placement

Bolt Metals Closes Second Tranche of LIFE Offering and Completes Unit Private Placement

Bolt Metals Closes Second Tranche of LIFE Offering and Completes Unit Private Placement

Bolt Metals Closes First Tranche of LIFE Offering

Bolt Biotherapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update

Bolt Metals Announces Consolidation Of Common Shares

Bolt Metals Closes $600,000 Non-Brokered Private Placement

Bolt Biotherapeutics Provides Update on BDC-4182 and Extends Cash Runway into 2027

Bolt Metals Announces Non-Brokered Private Placement

Bolt Metals Appoints Mr. Zachary Kotowych as Chief Executive Officer and Director

Bolt Biotherapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update

Bolt Metals Completes Debt Settlement

Bolt Metals Announces Debt Settlements

Bolt Metals Announces Debt Settlement

Bolt Biotherapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

Bolt Biotherapeutics to Host KOL Conference Call and Webcast to Discuss BDC-3042 Phase 1 Results and Corporate Updates

Bolt Biotherapeutics Presents Preclinical Results for Next-Generation Boltbody(TM) ISACs targeting CEA and PD-L1 at AACR Annual Meeting 2025

Bolt Biotherapeutics Presents Results from the Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics to Present Data from Phase 1 Dose-Escalation Clinical Study of BDC-3042 at AACR Annual Meeting 2025

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Provides Business Update

Bolt Biotherapeutics to Participate in Upcoming March Conferences

Bolt Metals Closes Debt Settlements

Bolt Biotherapeutics, Inc. Provides Update on Global Cancer Immunotherapy Co-Development with Toray Industries, Inc.

Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting

Bolt Biotherapeutics, Inc. May Have Violated Securities Laws And Shareholders Are Urged To Participate In A Case With The Schall Law Firm

The Schall Law Firm Invites Investors To Contribute To A Securities Fraud Lawsuit Against Bolt Biotherapeutics Inc

Bolt Biotherapeutics Inc. May Have Violated Securities Regulations And Stakeholders Are Urged To Reach Out To The Schall Law Firm

BOLT DEADLINE TODAY: ROSEN, A LEADING LAW FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

FINAL BOLT DEADLINE: Bronstein, Gewirtz & Grossman LLC Reminds Bolt Biotherapeutics, Inc. Investors to Join the Class Action Lawsuit!

FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

The Schall Law Firm Invites Investors In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Lawsuit

BOLT DEADLINE TOMORROW: ROSEN, NATIONAL TRIAL LAWYERS, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Stakeholders Can Contact The Schall Law Firm About Joining A Case Against Bolt Biotherapeutics Inc. For Securities Law Infractions

DEADLINE REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

BOLT DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

A Securities Fraud Lawsuit Has Been Filed On Behalf Of Investors In Bolt Biotherapeutics Inc And The Schall Law Firm Wants Affected Investors To Reach Out

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Bolt

BOLT DEADLINE TUESDAY: ROSEN, A LEADING NATIONAL FIRM, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

Bolt Biotherapeutics Inc. Is Being Sued For Possibly Engaging In Securities Related Infractions And Shareholders Can Assist The Schall Law Firm

BOLT DEADLINE NOTICE: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Bolt Biotherapeutics, Inc. Investors to Secure Counsel Before Important September 3 Deadline in Securities Class Action - BOLT

The Schall Law Firm Is Looking For Investors With Losses In Bolt Biotherapeutics Inc To Participate In A Securities Fraud Case

Bolt Biotherapeutics Inc. Is Being Sued For Securities Law Violations And Stockholders Are Invited To Contact The Schall Law Firm